To see the other types of publications on this topic, follow the link: HCV.

Journal articles on the topic 'HCV'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'HCV.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

CRAMP, M. E. "HBV + HCV = HCC?" Gut 45, no. 2 (1999): 168–69. http://dx.doi.org/10.1136/gut.45.2.168.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Paula, Cácia Régia de, Karynne Borges Cabral, Hildete Oliveira Ferreira Dos Prazeres, et al. "Tendência temporal das hepatites virais: A, B, C e B+ C, no estado de Goiás: estudo ecológico." CONTRIBUCIONES A LAS CIENCIAS SOCIALES 18, no. 2 (2025): e15300. https://doi.org/10.55905/revconv.18n.2-111.

Full text
Abstract:
Este estudo teve como objetivo, avaliar a tendência das notificações de hepatite viral A (HAV), hepatite viral B (HBV), hepatite viral C (HCV), e coinfecção de HBV + HCV. Trata-se de estudo de série temporal com dados secundários das notificações de hepatites virais: HAV, HBV, HCV e coinfecção de HBV + HCV em Goiás, entre os anos de 2010 e 2020. Os dados foram obtidos do SINAN, disponibilizados pelo DATASUS. As variáveis sociodemográficas analisadas incluíram sexo e faixa etária. As análises de tendência da série temporal foram realizadas por regressão linear pelo método de Prais-Winsten com v
APA, Harvard, Vancouver, ISO, and other styles
3

Mujeeb, Syed Abdul, Qamar Jamal, Rafique Khanani, Nayyer Iqbal, and Shahnaz Kaher. "Prevalence of Hepatitis B Surface Antigen and HCV Antibodies in Hepatocellular Carcinoma Cases in Karachi, Pakistan." Tropical Doctor 27, no. 1 (1997): 45–46. http://dx.doi.org/10.1177/004947559702700117.

Full text
Abstract:
Hepatocellular carcinoma (HCC) is a common cancer the world over. In Pakistan it has an incidence of 8/100 000 per annum. To assess the prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections in biopsy proven cases of HCC a serological study was conducted at Screening Laboratory of Blood Transfusion Services, Jinnah Postgraduate Medical Centre. Of 54 sera of HCC tested for HBV and HCV infections, 67% showed HBV infection, and 33% HCV infection. Among them 24% were positive for both HBV and HCV infections. No HBV and HCV infection was found in 24% cases of HCC. Our findings
APA, Harvard, Vancouver, ISO, and other styles
4

Stroffolini, Tommaso, and Giacomo Stroffolini. "A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma." Cancers 15, no. 8 (2023): 2388. http://dx.doi.org/10.3390/cancers15082388.

Full text
Abstract:
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading cause of hepatocellular carcinoma (HCC) worldwide. Currently, HBV-related HCC predominates in Sub-Saharan Africa and South-East-Asia, while HCV-related HCC predominates in northern Africa and in the western world. Liver cirrhosis is the underlying condition in most HBV cases and in nearly all HCV cases. Several cofactors, viral and non-viral, play a role in the progression toward HCC: dual HBV/HCV infection, HDV, HIV, alcohol intake, smoking, diabetes mellitus, obesity, and NAFLD/NASH. HBV vaccine is effective in preventing bo
APA, Harvard, Vancouver, ISO, and other styles
5

Huang, Yen-Tsung, Chin-Lan Jen, Hwai-I. Yang, et al. "Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C." Journal of Clinical Oncology 29, no. 27 (2011): 3643–50. http://dx.doi.org/10.1200/jco.2011.36.2335.

Full text
Abstract:
PurposeBoth hepatitis B (HBV) and C viruses (HCV) are causes of hepatocellular carcinoma (HCC), but lifetime risk and sex difference remain unclear. This study aimed to assess the lifetime risk and sex difference of HCC among patients with chronic HBV and/or HCV.MethodsA prospective cohort of 23,820 residents of Taiwan age 30 to 65 years were enrolled from 1991 to 1992, with 477 instances of HCC occurring subsequently. Serum samples collected at enrollment were tested for seromarkers and viral load of HBV and HCV. Newly developed HCC was ascertained through computerized data linkage with natio
APA, Harvard, Vancouver, ISO, and other styles
6

Pár, Alajos. "Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma." Orvosi Hetilap 150, no. 1 (2009): 19–26. http://dx.doi.org/10.1556/oh.2009.28529.

Full text
Abstract:
Mivel a hepatitis B- és C-vírus- (HBV-, HCV-) fertőzés döntő szerepet játszik a hepatocellularis carcinoma (HCC) keletkezésében, a HBV és HCV okozta hepatitis és cirrhosis megelőzése és kezelése egyben a HCC prevencióját is jelentheti. A HCC primer prevencióját képviseli a HBV elleni vakcináció és a donorok szűrése HBV- és HCV-markerekre. A szekunder prevencióhoz sorolható az interferonalapú és/vagy nukleozidanalóg anti-HBV- és anti-HCV-terápia, a cirrhosisos betegek HCC irányában történő alfa-foetoprotein + ultrahang szűrése, valamint a HCC kuratív reszekciója/ablatiója utáni adjuváns antivir
APA, Harvard, Vancouver, ISO, and other styles
7

Haberl, Elisabeth M., Thomas S. Weiss, Georg Peschel, et al. "Liver Lipids of Patients with Hepatitis B and C and Associated Hepatocellular Carcinoma." International Journal of Molecular Sciences 22, no. 10 (2021): 5297. http://dx.doi.org/10.3390/ijms22105297.

Full text
Abstract:
Hepatocellular carcinoma (HCC) still remains a difficult to cure malignancy. In recent years, the focus has shifted to lipid metabolism for the treatment of HCC. Very little is known about hepatitis B virus (HBV) and C virus (HCV)-related hepatic lipid disturbances in non-malignant and cancer tissues. The present study showed that triacylglycerol and cholesterol concentrations were similar in tumor adjacent HBV and HCV liver, and were not induced in the HCC tissues. Higher levels of free cholesterol, polyunsaturated phospholipids and diacylglycerol species were noted in non-tumorous HBV compar
APA, Harvard, Vancouver, ISO, and other styles
8

Fang, Lily, Amanda Yu, and Jane A. Buxton. "Identification of Acute Vaccine-Preventable Hepatitis in Individuals with Chronic Hepatitis in British Columbia between 1991 and 2007." Canadian Journal of Infectious Diseases and Medical Microbiology 22, no. 1 (2011): 10–14. http://dx.doi.org/10.1155/2011/564290.

Full text
Abstract:
BACKGROUND: In British Columbia (BC), hepatitis A virus (HAV) and hepatitis B virus (HBV) vaccines are provincially funded for persons with chronic hepatitis infections. PURPOSE: To assess the effectiveness of BC public health follow-up of HBV and hepatitis C virus (HCV) cases and immunization policy by determining the number of vaccine-preventable acute hepatitis infections reported following a chronic HBV or HCV diagnosis, by examining demographic characteristics and by observing temporal trends.METHODS: All newly identified cases of HAV, HBV and HCV between 1991 and October 2007 were extrac
APA, Harvard, Vancouver, ISO, and other styles
9

Buxton, Jane A., and Jin Hee Kim. "Hepatitis A and Hepatitis B Vaccination Responses in Persons with Chronic Hepatitis C Infections: A Review of the Evidence and Current Recommendations." Canadian Journal of Infectious Diseases and Medical Microbiology 19, no. 2 (2008): 197–202. http://dx.doi.org/10.1155/2008/410362.

Full text
Abstract:
In persons with chronic hepatitis C virus (HCV) infections, superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) can cause serious complications, including fulminating hepatitis or increased severity of hepatitis. Therefore, it is important to adequately protect persons with chronic HCV infections by immunization. Suboptimal response to vaccines has been reported in patients with chronic liver disease. The present article reviews HAV and HBV vaccine responses reported in the literature when administered to individuals with chronic HCV infection, and reviews current national and
APA, Harvard, Vancouver, ISO, and other styles
10

Shen, Yu-Chuan, Hui-Ching Hsu, Tzu-Min Lin, et al. "H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection." Journal of Clinical Oncology 40, no. 11 (2022): 1206–19. http://dx.doi.org/10.1200/jco.21.01802.

Full text
Abstract:
PURPOSE H1-antihistamines (AHs) may exert protective effects against cancer. This study investigated the association of AH use with the risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV-HCV virus infection. MATERIALS AND METHODS Patients with HBV, HCV, or dual HBV-HCV infection were enrolled from Taiwan's National Health Insurance Research Database and examined for the period from January 1, 2006, to December 31, 2015. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the association between A
APA, Harvard, Vancouver, ISO, and other styles
11

Alhamadany, Alaa Younis Mahdy, and Wajdi Sabeeh Sadek. "Analysis of the Chromosomal Aberrations in Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Hepatocellular Carcinoma Patients (HCC) in Mosul City, Iraq." NTU Journal of Pure Sciences 1, no. 2 (2022): 48–53. http://dx.doi.org/10.56286/ntujps.v1i2.210.

Full text
Abstract:
Abstract. Hepatocellular carcinoma (HCC) (also known as liver cancer) is one of the most frequent cancers in humans. HCC is linked to chronic hepatitis B and C virus infection, cirrhosis, and excessive alcohol consumption. The aim of this study was to use Metaphase chromosome analysis in whole blood to determine chromosomal aberrations (CA) in HBV, HCV, and HCC patients. A cohort of 145 samples have been collected from participants from the date of 5 \ 1 \ 2020 to 15\9\ 2021. Among those samples are (40 healthy controls, HBV 38, 44 HCV, and HCC 23) to make cytogenetic evaluation by observing t
APA, Harvard, Vancouver, ISO, and other styles
12

Kuo, Yuan-Hung, Tzu-Hsin Huang, Jing-Houng Wang, et al. "Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib." Cancers 14, no. 16 (2022): 3971. http://dx.doi.org/10.3390/cancers14163971.

Full text
Abstract:
Without analyzing the status of viremia, hepatitis C virus-related hepatocellular carcinoma (HCV-HCC) patients are proposed to have better prognosis than hepatitis B virus-related HCC (HBV-HCC) patients using sorafenib. We aimed to elucidate the efficacy of concurrent sorafenib and anti-viral treatment for HCC patients with HBV or HCV infection in real world. Between January 2018 and January 2021, 256 unresectable HCC patients receiving first-line sorafenib were evaluated. High-potency nucleoside analogs were used for HBV control, whereas direct-acting antivirals were administered for HCV erad
APA, Harvard, Vancouver, ISO, and other styles
13

Alhamadany, Alaa Younis Mahdy, and Wajdi Sabeeh Sadek. "Evaluation of the genotoxicity in patients with HBV, HCV, and HCC using micronucleus and comet assay in Mosul City\Iraq." International journal of health sciences 6, S1 (2022): 1567–79. http://dx.doi.org/10.53730/ijhs.v6ns1.4903.

Full text
Abstract:
Hepatitis B virus (HBV) and hepatitis C virus (HCV) have mutagenic effects on somatic cells. HBV and HCV may be showing these mutagenic effects through its viral proteins or through integrating into host DNA. The aim of this study was to determine whether HBV and HCV have a genotoxic effect on the DNA of oral epithelial cells. A cohort of 145 samples have been collected from participants from the date of 5 \ 1 \ 2020 to 15\9\ 2021. Among those samples are (40 healthy controls, HBV 38, 44 HCV, and HCC 23) to make cytogenetic evaluation by observing the micronucleus (MNi) test and comet assay. F
APA, Harvard, Vancouver, ISO, and other styles
14

Mbaga, Donatien Serge, Sebastien Kenmoe, Cyprien Kengne-Ndé, et al. "Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders." PLOS ONE 17, no. 1 (2022): e0262903. http://dx.doi.org/10.1371/journal.pone.0262903.

Full text
Abstract:
Introduction Africa denotes unique facies for hepatocellular carcinoma (HCC) characterized by a conjunction of low sensitization, restricted access to diagnosis and treatment and associated with the highest incidence and mortality in the world. We investigated whether hepatitis B (HBV), C (HCV) and D (VHD) viruses were etiological agents of HCC in Africa. Methods Relevant articles were searched in PubMed, Web of Science, African Index Medicus, and African Journal Online databases, as well as manual searches in relevant reviews and included articles. Analytical studies from Africa evaluating th
APA, Harvard, Vancouver, ISO, and other styles
15

Sethi, Amna Ameen, and Nisar Ahmed Shar. "Molecular insights into the viral etiologies in liver cancer." Pakistan Journal of Science 76, no. 04 (2024): 522–29. https://doi.org/10.57041/vol76iss04pp522-529.

Full text
Abstract:
Hepatitis B (HBV) and Hepatitis C (HCV) viruses are the main causes of viral hepatitis, which greatly increases the incidence of liver cancer worldwide, especially hepatocellular carcinoma (HCC). The infections caused by HBV and HCV can progress from acute to chronic stages, with an increased risk for HCC due to the promotion of cirrhosis. Therefore, it is essential to understand the molecular mechanisms of HBV and HCV attachment, and entry into human cells for developing targeted therapies and preventive measures. This study identifies and analyzes the functional receptors involved in HBV and
APA, Harvard, Vancouver, ISO, and other styles
16

Alhamadany, Alaa Younis Mahdy, and Wajdi Sabeeh Sadek. "Evaluation of the genotoxicity and genomic instability in patients with HBV, HCV and HCC using micronucleus and comet assay." NTU Journal of Pure Sciences 1, no. 2 (2022): 54–63. http://dx.doi.org/10.56286/ntujps.v1i2.214.

Full text
Abstract:
On somatic cells, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) are mutagenic. HBV and HCV may be causing these mutagenesis effects via integrating into host DNA or by viral proteins. The purpose of this research was to investigate if HBV and HCV had a genotoxic effect on renal epithelial cells' DNA. A total of 145 samples were taken from participants between the periods of 5 \1 2020 and 15\9 2021. (40 healthy controls, HBV 38, 44 HCV, and HCC 23) were used to perform cytogenetic analysis in renal epithelial cells using the micronucleus (MNi) test and comet assay. For the comet e
APA, Harvard, Vancouver, ISO, and other styles
17

Jiang, Joy, Meredith S. Shiels, Donna Rivera, Marc G. Ghany, Eric A. Engels, and Thomas R. O’Brien. "Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans." PLOS ONE 19, no. 11 (2024): e0307746. http://dx.doi.org/10.1371/journal.pone.0307746.

Full text
Abstract:
Background Incidence of hepatocellular carcinoma (HCC) had been increasing steadily among older Americans but plateaued in 2015–2017. Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) are important causes of HCC. The impact of improved treatments for these infections on recent trends in HCC incidence is unclear. Aims To examine the relationship between use of antiviral therapy for chronic viral hepatis and HCC incidence in older Americans. Methods We used 2007–2017 data from the Surveillance, Epidemiology, and End Results—Medicare database to estimate age-standardized i
APA, Harvard, Vancouver, ISO, and other styles
18

Dickson-Spillmann, Maria, Severin Haug, Ambros Uchtenhagen, Philip Bruggmann, and Michael P. Schaub. "Rates of HIV and Hepatitis Infections in Clients Entering Heroin-Assisted Treatment between 2003 and 2013 and Risk Factors for Hepatitis C Infection." European Addiction Research 22, no. 4 (2015): 181–91. http://dx.doi.org/10.1159/000441973.

Full text
Abstract:
Background/Aims: We report on the rates of hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in 1,313 clients entering heroin-assisted treatment (HAT) in Switzerland from 2003 to 2013. We identify predictors of HCV infection. Methods: Data were collected using questionnaires within 2 weeks of clients' first entry into HAT. Prevalence of HAV, HBV, HCV and HIV was calculated using laboratory test results collected at entry or using reports of older test results. Predictors of HCV status were identified through multiple logistic regre
APA, Harvard, Vancouver, ISO, and other styles
19

von Drygalski, Annette, Niamh O'Connell, Peter Verhamme, et al. "Adult Patients with Hemophilia B and with a History of Chronic HCV/HBV Infection Receiving Liver-Directed Gene Therapy Demonstrated Long-Term Bleeding Protection and Sustained FIX Activity: Efficacy and Safety Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec." Blood 142, Supplement 1 (2023): 2258. http://dx.doi.org/10.1182/blood-2023-188921.

Full text
Abstract:
Introduction: Liver-targeted recombinant adeno-associated virus (rAAV) gene therapy for hemophilia B has recently become a real-world therapeutic option for an adult population burdened with prevalent co-morbid chronic hepatitis C virus (HCV) and hepatitis B virus (HBV). The pivotal phase 3 HOPE-B trial (NCT03489291) evaluated the efficacy and safety of etranacogene dezaparvovec (CSL222, formerly AMT-061), an AAV5 vector, containing a codon-optimized, highly active factor IX (FIX) Padua R338L transgene under the control of the liver-specific promoter LP-1. Here we evaluate the efficacy and saf
APA, Harvard, Vancouver, ISO, and other styles
20

Navas, Maria-Cristina, Iris Suarez, Andrea Carreño, et al. "Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia." Hepatitis Research and Treatment 2011 (October 31, 2011): 1–10. http://dx.doi.org/10.1155/2011/582945.

Full text
Abstract:
Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related death worldwide. Globally, the most important HCC risk factors are Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV), chronic alcoholism, and dietary exposure to aflatoxins. We have described the epidemiological pattern of 202 HCC samples obtained from Colombian patients. Additionally we investigated HBV/HCV infections and TP53 mutations in 49 of these HCC cases. HBV biomarkers were detected in 58.1% of the cases; HBV genotypes F and D were characterized in three of the samples. The HCV biomarker was detected in 37% of th
APA, Harvard, Vancouver, ISO, and other styles
21

Yaro, Abubakar, Svetoslav Martinov, and Catherine Johnson. "Efficacy of combined antiretroviral therapy (cART) in Hepatitis B and C associated hepatocellular carcinoma (HCC): a narrative review." Journal of Human Virology & Retrovirology 10, no. 3 (2023): 73–78. http://dx.doi.org/10.15406/jhvrv.2023.10.00271.

Full text
Abstract:
Introduction: HCC is the 3rd leading cancers in the world. Majority of HCC are due to chronic viral hepatitis including HBV, HCV, and HDV. Progression to cirrhosis and HCC in HBV and HCV infection is linked to level of replication and high serum viral DNA load. The use of antiviral agents is an effective strategy of treating HBV- and HCV- associated HCC. Aim: To assess the effectiveness of combined antiretroviral therapy on HBV and HCV-associated HCC Method: A narrative review of literature involving RCT and observational studies was performed. Blinding scores was used to evaluate the quality
APA, Harvard, Vancouver, ISO, and other styles
22

Minuk, GY, M. Zhang, SGM Wong, et al. "Viral Hepatitis in a Canadian First Nations Community." Canadian Journal of Gastroenterology 17, no. 10 (2003): 593–96. http://dx.doi.org/10.1155/2003/978162.

Full text
Abstract:
Serological markers for hepatitis A (HAV), B (HBV) and C (HCV) were documented in 315 inhabitants (27%) of a central Manitoba First Nations community. Serologic evidence of HAV infection (anti-HAV positive) was almost universal (92%) by the age of 20 years. HBV infection (antibody to hepatitis B core antigen positive) had occurred in only 2.3% of the study population and no chronic carriers were identified. Serological evidence of HCV infection (anti-HCV positive) was documented in 2.2% of the population but ongoing viremia (HCV-RNA positive by polymerase chain reaction) was absent. The result
APA, Harvard, Vancouver, ISO, and other styles
23

Lu, Meng-Chuan, Ying-Hsuen Wu, Chi-Hsiang Chung, et al. "Association of Hepatitis B and C Virus with the Risk of Coronary Artery Disease and Cerebrovascular Disease in Patients with Hepatocellular Carcinoma." Journal of Clinical Medicine 12, no. 7 (2023): 2602. http://dx.doi.org/10.3390/jcm12072602.

Full text
Abstract:
Background: Hepatocellular carcinoma accounts for approximately 90% of primary liver cancers and hepatitis virus was believed to have the potential for altering the pathogenesis of arteriosclerosis. However, the influence of the hepatitis virus on coronary artery disease or cerebral vascular disease remains unclear. This study used the Taiwan National Health Insurance Research Database to clarify the virus-associated risk of coronary artery disease and cerebral vascular disease in patients with hepatocellular carcinoma (HCC). Methods: A total of 188,039 HCC individuals, age 20 years or older,
APA, Harvard, Vancouver, ISO, and other styles
24

Duan, Jingxian, Tianhao Mu, and Shifu Chen. "The mutation profiles of HBV or HCV infected hepatocellular carcinoma patients underlie the varied responses to second-line immunotherapy." Journal of Clinical Oncology 38, no. 15_suppl (2020): e16629-e16629. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16629.

Full text
Abstract:
e16629 Background: HBV and HCV infections facilitate the development of hepatocellular carcinoma (HCC) via different mechanisms, given that the DNA sequence of HBV but not HCV can integrate into the host genome. However, it remains unclear that whether the altered genomic landscape of HCC patients caused by HBV or HCV infection may result in different responses to treatments. Methods: The MSK panel sequencing results and treatment data of 127 HCC patients were downloaded from the TCGA database (MSK, Clin Cancer Res 2018). Profiles of HBV positive and HCV positive patients were extracted. Based
APA, Harvard, Vancouver, ISO, and other styles
25

Liu, Weibo. "The transmission route of hepatitis A, B, and C virus and its pathological changes on the liver." Theoretical and Natural Science 48, no. 1 (2024): 15–21. http://dx.doi.org/10.54254/2753-8818/48/2024pj0111.

Full text
Abstract:
This study explored the globally prevalent pathogens, hepatitis viruses, and their significant impact on human health. This article mainly focuses on HAV, HBV, and HCV, aiming to provide a comprehensive reference for future studies. HAV is mainly transmitted through the gastrointestinal tract, while HBV and HCV are mainly transmitted through blood, body fluids, sexual contact, and mother-to-child transmission. Pathologically, HAV is mostly acute, while HBV and HCV tend to be chronic, which can easily lead to cirrhosis and even liver cancer. Analyzing the transmission mechanism and pathological
APA, Harvard, Vancouver, ISO, and other styles
26

Schotten, Clemens, Bastian Ostertag, Jan-Peter Sowa, et al. "GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients." Pharmaceuticals 14, no. 8 (2021): 735. http://dx.doi.org/10.3390/ph14080735.

Full text
Abstract:
Despite vaccination programs and direct antiviral treatments, the incidence of virus-related hepatocellular carcinoma (HCC) remains high, while ultrasound-based detection rates for early-stage HCC is continuously low. To address this insufficiency, we set out to characterize whether the GALAD score, which incorporates gender, age, and serum levels of AFP, AFP isoform L3 (AFP-L3), and des-gamma-carboxy-prothrombin (DCP), can improve early-stage HCC detection in a Caucasian HBV/HCV cohort. In a retrospective German single-center study, 182 patients with HBV, 223 with HCV and 168 with other etiol
APA, Harvard, Vancouver, ISO, and other styles
27

Awadh, Abdullah A., Abdulrahman A. Alharthi, Basil A. Alghamdi, et al. "Coinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis." Journal of Global Infectious Diseases 16, no. 4 (2024): 127–34. https://doi.org/10.4103/jgid.jgid_211_23.

Full text
Abstract:
Introduction: Hepatitis B and C are viral infections causing chronic liver inflammation and, when left untreated, lead to cirrhosis and a risk for hepatocellular carcinoma, the most common type of primary liver cancer with high mortality. The hepatitis B virus-hepatitis C virus (HBV-HCV) coinfection leads to a faster progression to advanced liver diseases and higher hepatocellular carcinoma (HCC) risk than monoinfection. Unlike the relative risk for HCC due to either HBV or HCV, no recent analysis of the risk for HBV-HCV coinfection exists. Methods: Based on PRISMA recommendations and guidelin
APA, Harvard, Vancouver, ISO, and other styles
28

Rahman, Md Tahminur, Rosy Sultana, and Sohel Reza Chowdhury. "Seropositivity and pattern of viral hepatitis in clinically suspected cases of hepatitis in Dhaka city." Bangladesh Medical Research Council Bulletin 33, no. 3 (2010): 103–6. http://dx.doi.org/10.3329/bmrcb.v33i3.1142.

Full text
Abstract:
An attempt was made to see the seropositivity and pattern of four common hepatotrophic viruses (HBV, HCV, HEV, HAV) in patients suspected to have been suffering from viral hepatitis. Blood samples from 2,995 cases of suspected HBV infection, 331 from HCV, 155 from HEV and 24 from HAV were tested for these viral markers. Of these a total of 245 (8.1%) were positive for HBsAg, 18 (5.4%) for HCV, 87 (56.1%) for HEV and 8 (33.3%) were positive for HAV infection. The predominant age group affected in HBV is 25-40 years, for HCV >61 years, HEV 26-50 years and HAV under 11 years. Seropositivity fo
APA, Harvard, Vancouver, ISO, and other styles
29

Alqahtani, Saleh A., and Massimo Colombo. "Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma." Cells 10, no. 11 (2021): 3091. http://dx.doi.org/10.3390/cells10113091.

Full text
Abstract:
Chronic infections with either hepatitis B or C virus (HBV or HCV) are among the most common risk factors for developing hepatocellular carcinoma (HCC). The hepatocarcinogenic potential of these viruses is mediated through a wide range of mechanisms, including the induction of chronic inflammation and oxidative stress and the deregulation of cellular pathways by viral proteins. Over the last decade, effective anti-viral agents have made sustained viral suppression or cure a feasible treatment objective for most chronic HBV/HCV patients. Given the tumorigenic potential of HBV/HCV, it is no surp
APA, Harvard, Vancouver, ISO, and other styles
30

Shao, Yu Yun, Min-Shu Hsieh, Chung-Yi Huang, Yung-Ling Chang, Chih-Hung Hsu, and Ann-Lii Cheng. "Vascular endothelial growth factor expression in hepatitis C virus (HCV)-related advanced hepatocellular carcinoma (HCC) compared with hepatitis B virus (HBV)-related advanced HCC." Journal of Clinical Oncology 31, no. 15_suppl (2013): 4115. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4115.

Full text
Abstract:
4115 Background: HCC with different etiologic factors may result in activation of different signaling pathways. This study aimed to clarify if HBV-related HCC (HBV-HCC) and HCV-related HCC (HCV-HCC) may have difference in the expression of key molecules that are relevant to contemporary molecular targeted therapy. Methods: We enrolled patients diagnosed with advanced HCC from 2001 to 2011 who had tumor tissues obtained upon the diagnosis of advanced HCC at our center. Tumor slides were immunohistochemically stained for phosphorylated extracellular signal-regulated kinases (p-ERK), Raf kinase i
APA, Harvard, Vancouver, ISO, and other styles
31

Galy, Olivier, Isabelle Chemin, Emilie Le Roux, et al. "Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand." Hepatitis Research and Treatment 2011 (June 30, 2011): 1–9. http://dx.doi.org/10.1155/2011/697162.

Full text
Abstract:
Hepatocellular carcinoma (HCC) may develop according to two major pathways, one involving HBV infection and TP53 mutation and the other characterized by HCV infection and CTNNB1 mutation. We have investigated HBV/HCV infections and TP53/CTNNB1 mutations in 26 HCC patients from Thailand. HBV DNA (genotype B or C) was detected in 19 (73%) of the cases, including 5 occult infections and 3 coinfections with HCV. TP53 and CTNNB1 mutations were not mutually exclusive, and most of TP53 mutations were R249S, suggesting a significant impact of aflatoxin-induced mutagenesis in HCC development.
APA, Harvard, Vancouver, ISO, and other styles
32

Aimla, Kerstin, Justyna Dominika Kowalska, Raimonda Matulionyte, et al. "Vaccination against HBV and HAV as Mode of Hepatitis Prevention among People Living with HIV—Data from ECEE Network Group." Vaccines 11, no. 5 (2023): 980. http://dx.doi.org/10.3390/vaccines11050980.

Full text
Abstract:
(1) Background: Viral hepatitis C (HCV) and viral hepatitis B (HBV) are common co-infections in people living with HIV (PLWH). All PLWH should be vaccinated against HBV and hepatitis A (HAV) and treated for HBV and HCV. We aimed to compare testing, prophylaxis and treatment of viral hepatitis in PLWH in Central and Eastern Europe (CEE) in 2019 and 2022. (2) Methods: Data was collected through two on-line surveys conducted in 2019 and 2022 among 18 countries of the Euroguidelines in CEE (ECEE) Network Group. (3) Results: In all 18 countries the standard of care was to screen all PLWH for HBV an
APA, Harvard, Vancouver, ISO, and other styles
33

Hester, Caitlin A., Nicole E. Rich, Amit G. Singal, and Adam C. Yopp. "Comparative Analysis of Nonalcoholic Steatohepatitis– Versus Viral Hepatitis– and Alcohol-Related Liver Disease–Related Hepatocellular Carcinoma." Journal of the National Comprehensive Cancer Network 17, no. 4 (2019): 322–29. http://dx.doi.org/10.6004/jnccn.2018.7105.

Full text
Abstract:
Background: Despite an increasing burden of nonalcoholic steatohepatitis (NASH), limited data are available comparing outcomes of NASH-related hepatocellular carcinoma (HCC) versus other etiologies. Methods: Patient demographic and tumor characteristics were collected for 1,051 patients diagnosed with NASH-, alcohol-related liver disease (ALD)–, hepatitis C virus (HCV)–, and hepatitis B virus (HBV)–related HCC at 2 large health systems from January 2008 through December 2016. Patient demographics, clinical characteristics, and survival were compared. Risk-adjusted treatment receipt and overall
APA, Harvard, Vancouver, ISO, and other styles
34

Kaliaskarova, Kulpash. "Aspects of Cancer Prevention of the Main Precursors of Liver Carcinoma - Viral hepatitis." Oncology.kz, no. 8 (August 15, 2023): 13–17. https://doi.org/10.56598/2957-6377-2023-8-13-17.

Full text
Abstract:
The vast majority of hepatocellular carcinoma (HCC) tumors arise from liver cirrhosis (LC), which in turn is most often caused by infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).The purpose of the study: to assess the dynamics of the prevalence of HBV and HCV as one of the factors in the development of cirrhosis and HCC.Methods. A retrospective analysis of the prevalence of HBV, HCV, LC and HCC over a 10-year period (2013-2022) was carried out. The dynamics of the incidence of HCV and HBV infections from 2020 to 2022 was also studied. The work used data from the Information S
APA, Harvard, Vancouver, ISO, and other styles
35

Akashi, Hayato, and Masaaki Hidaka. "Comparison of the pathological features among HBV, HCV, and nonviral etiology-related hepatocellular carcinoma using explanted whole liver examinations." Journal of Clinical Oncology 35, no. 4_suppl (2017): 245. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.245.

Full text
Abstract:
245 Background: The aim of this study is to compare the pathological features among HBV, HCV and non-viral etiology related hepatocellular carcinoma (HCC) in the explanted cirrhotic liver using whole liver examinations. Methods: Ninety patients (HBV 23, HCV 53, HBV+HCV 3, nonBnonC 16) out of 246 recipients of liver transplantation were analyzed. All specimens were sectioned serially at 5-7 mm intervals and then were examined by an experienced pathologist. The pathological characteristics of HCC among each group were retrospectively analyzed using whole liver thin sliced histological examinatio
APA, Harvard, Vancouver, ISO, and other styles
36

Patt, Y. Z., C. Charnsangavej, B. Yoffe, et al. "Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival." Journal of Clinical Oncology 12, no. 6 (1994): 1204–11. http://dx.doi.org/10.1200/jco.1994.12.6.1204.

Full text
Abstract:
PURPOSE To conduct a pilot trial of hepatic arterial infusion (HAI) of floxuridine (FUDR), leucovorin, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (FLAP) in nonresectable hepatocellular cancer (HCC) confined to the liver and assess the effects of hepatitis B (HBV) and hepatitis C (HCV) viral markers on toxicity, response to treatment, and patient survival. PATIENTS AND METHODS Of 31 HCC patients, 13 were HBV- and HCV-nonreactive, and 18 had evidence of either current or prior HBV and/or HCV infection. Treatment was delivered through percutaneous hepatic arterial c
APA, Harvard, Vancouver, ISO, and other styles
37

Cortes-Mancera, Fabian, Carmen Luisa Loureiro, Sergio Hoyos, et al. "Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia." Hepatitis Research and Treatment 2011 (September 20, 2011): 1–10. http://dx.doi.org/10.1155/2011/363205.

Full text
Abstract:
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the principal risk factor associated to end-stage liver diseases in the world. A study was carried out on end-stage liver disease cases admitted to an important hepatology unit in Medellin, the second largest city in Colombia. From 131 patients recruited in this prospective study, 71% of cases were diagnosed as cirrhosis, 12.2% as HCC, and 16.8% as cirrhosis and HCC. Regarding the risk factors of these patients, alcohol consumption was the most frequent (37.4%), followed by viral etiology (17.6%). Blood and/or hepatic tissue sa
APA, Harvard, Vancouver, ISO, and other styles
38

Cranford, Hannah M., Patricia Denise Jones, Qinran Liu, Tulay Koru-Sengul, Isildinha M. Reis, and Paulo S. Pinheiro. "Hepatocellular carcinoma etiology drives survival outcomes: A population-based analysis." Journal of Clinical Oncology 42, no. 16_suppl (2024): e16142-e16142. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e16142.

Full text
Abstract:
e16142 Background: Previous studies on survival differences according to etiology of hepatocellular carcinoma (HCC) (5-year observed survival of 23%) are limited to hospital-based series and restricted cohorts. We performed a population-based survival analysis by major HCC etiologies, inclusive of hepatitis-C virus (HCV), hepatitis-B virus (HBV), alcohol-related liver disease (ALD), and non-alcoholic fatty liver disease (NAFLD) as singular causes, in addition to unexplored dual etiological groups, (HCV&HBV, HCV&ALD, and HBV&ALD), and accounting for age at diagnosis, tumor character
APA, Harvard, Vancouver, ISO, and other styles
39

Petruzziello, Arnolfo. "Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma." Open Virology Journal 12, no. 1 (2018): 26–32. http://dx.doi.org/10.2174/1874357901812010026.

Full text
Abstract:
Introduction:Hepatocellular carcinoma (HCC) is one of the most prevalent primary malignant tumors and accounts for about 90% of all primary liver cancers. Its distribution varies greatly according to geographic location and it is more common in middle and low- income countries than in developed ones especially in Eastern Asia and Sub Saharan Africa (70% of all new HCCs worldwide), with incidence rates of over 20 per 100,000 individuals.Explanation:The most important risk factors for HCC are Hepatitis B Virus (HBV) infection, Hepatitis C Virus (HCV) infection, excessive consumption of alcohol a
APA, Harvard, Vancouver, ISO, and other styles
40

Yen, Yi-Hao, Kwong-Ming Kee, Wei-Feng Li, et al. "Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology." Cancers 15, no. 6 (2023): 1687. http://dx.doi.org/10.3390/cancers15061687.

Full text
Abstract:
This study was conducted to determine whether the causes of death among patients with hepatocellular carcinoma (HCC) differ according to chronic liver disease (CLD) etiology. Between 2011 and 2020, 3977 patients who were newly diagnosed with HCC at our institution were enrolled in this study. We determined whether the cause of death was HCC-related and non-HCC-related. For patients with multiple CLD etiologies, etiology was classified using the following hierarchy: hepatitis C virus (HCV) > hepatitis B virus (HBV) > alcohol-related causes > all negative. All negative was defined as ne
APA, Harvard, Vancouver, ISO, and other styles
41

Tong, C. Y. W., R. Khan, N. J. Beeching, et al. "The occurrence of hepatitis B and C viruses in Pakistani patients with chronic liver disease and hepatocellula carcinoma." Epidemiology and Infection 117, no. 2 (1996): 327–32. http://dx.doi.org/10.1017/s0950268800001503.

Full text
Abstract:
SummaryTo study the occurrence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients with chronic liver disease (CLD) and hepatocellular carcinoma (HCC) in Pakistan, blood samples from 105 sequential patients with biopsy-proven CLD (n= 82) and HCC (n= 23) were tested for HBV and HCV markers. Of the 105, 87 (83%) had evidence of hepatitis B exposure, 58 (55%) were positive for hepatitis B surface antigen (HBsAg), 23 (22%) had hepatitis C antibodies and 25 (24%) had detectable HCV RNA. Significantly more patients with HCC had evidence of HBV exposure in the absence of HCV markers (4
APA, Harvard, Vancouver, ISO, and other styles
42

Pseush, S. Yu, L. V. Zozulya, and L. L. Mikhaleva. "The predictive value indicators of first trimester biochemical screening in assessing unfavorable factors of pregnancy course in women with HIV as well as hepatitis B and C." Obstetrics, Gynecology and Reproduction 15, no. 6 (2022): 686–94. http://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2021.240.

Full text
Abstract:
Aim: to find out the predictive value of blood serum biochemical parameters PAPP-A (pregnancy-associated plasma protein A) and β-hCG (beta subunit of human chorionic gonadotropin) in the assessment of unfavorable pregnancy outcomes in women infected by human immunodeficiency virus (HIV) as well as viral hepatitis B (HBV) and C (HCV).Materials and Methods. A retrospective study of the medical records from 52 women was carried out, including 19 HIV-infected women, 9 women with monoinfection HBV or HCV, 11 pregnant women who were co-infected (HIV/HBV or HIV/HCV) and 13 uninfected women. PAPP-A an
APA, Harvard, Vancouver, ISO, and other styles
43

Qiu, Jinrong, Weifeng Wang, Yingmei Li, and Shifu Chen. "Comparison of mutational landscape of non-alcoholic fatty liver disease, viral hepatitis, and alcohol consumption related hepatocellular carcinoma." Journal of Clinical Oncology 38, no. 15_suppl (2020): e16614-e16614. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16614.

Full text
Abstract:
e16614 Background: Hepatocellular cancer (HCC) is the seventh most common cancer and the fourth leading cause of cancer-related death worldwide. The most common risk factors of HCC have traditionally included hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol-related liver disease (ALD). Recently, Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as the fastest growing risk factor for the development of HCC. This study reports the mutation landscape of NAFLD-related hepatocellular carcinoma (HCC) versus other etiologies. Methods: Mutation data of 219 HCC samples were collected f
APA, Harvard, Vancouver, ISO, and other styles
44

Jain, Rajeev K., Rakesh Shrivastava, Shailendra K. Jain, et al. "Seropositivity and coinfection of hepatitis B and hepatitis C viruses in Central India: A hospital-based study." Journal of Family Medicine and Primary Care 13, no. 10 (2024): 4413–18. http://dx.doi.org/10.4103/jfmpc.jfmpc_202_24.

Full text
Abstract:
ABSTRACT Background: Hepatitis B virus (HBV) and Hepatitis C virus (HCV) show similarity in the transmission, distribution, hepatotropism, and leading to chronic asymptomatic infection. Coinfection of HBV and HCV can lead to more severe liver disease and an increased risk for progression to hepatocellular carcinoma (HCC). Most of the people with chronic infection are unaware of their HBV and HCV infections, hence facilitating these to go undiagnosed until these viruses have caused serious liver damage and they act as a potential source of infection for the community at large. Therefore, the pr
APA, Harvard, Vancouver, ISO, and other styles
45

Huang, Xiao-wen, Bing Liao, Yang Huang, et al. "Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?" Digestive Diseases 36, no. 3 (2018): 228–35. http://dx.doi.org/10.1159/000486196.

Full text
Abstract:
Aim: To confirm whether cirrhosis is indispensable for the non-invasive diagnostic criteria for hepatocellular carcinoma (HCC) in hepatitis B virus (HBV)-endemic areas. Methods: Between January 2014 and December 2014, a total of 409 patients with pathologically proven focal liver lesions who underwent contrast-enhanced ultrasound (CEUS) were recruited from our institution. Clinical liver cirrhosis, HBV/HCV infection and HCC-typical vascular pattern of the targeted lesion on CEUS were evaluated. The following 3 criteria were applied to these patients to diagnose HCC: criterion 1, clinical liver
APA, Harvard, Vancouver, ISO, and other styles
46

Kishta, Sara, Ashraf Tabll, Tea Omanovic Kolaric, Robert Smolic, and Martina Smolic. "Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals." Biomedicines 8, no. 6 (2020): 175. http://dx.doi.org/10.3390/biomedicines8060175.

Full text
Abstract:
Although hepatitis C virus (HCV) RNA may be eliminated from blood circulation by direct-acting antivirals (DAA) therapy as assessed by real-time polymerase chain reaction (PCR), HCV RNA can still be present in liver tissue, and this is known as occult HCV. There has been a lot of controversy surrounding the recurrence of hepatocellular carcinoma (HCC) after DAA treatment of hepatic cells infected with chronic HCV. One of the main risk factors that leads to de novo HCC is the chronicity of HCV in hepatic cells. There are many studies regarding the progression of HCV-infected hepatic cells to HC
APA, Harvard, Vancouver, ISO, and other styles
47

Kanda, Tatsuo, Taichiro Goto, Yosuke Hirotsu, Mitsuhiko Moriyama, and Masao Omata. "Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review." International Journal of Molecular Sciences 20, no. 6 (2019): 1358. http://dx.doi.org/10.3390/ijms20061358.

Full text
Abstract:
Almost all patients with hepatocellular carcinoma (HCC), a major type of primary liver cancer, also have liver cirrhosis, the severity of which hampers effective treatment for HCC despite recent progress in the efficacy of anticancer drugs for advanced stages of HCC. Here, we review recent knowledge concerning the molecular mechanisms of liver cirrhosis and its progression to HCC from genetic and epigenomic points of view. Because ~70% of patients with HCC have hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection, we focused on HBV- and HCV-associated HCC. The literature suggests t
APA, Harvard, Vancouver, ISO, and other styles
48

Andressa de Farias Fehlberg, Joelma Lessa da Silva, Roberta Pinho Gomes, and Rachel Siqueira de Queiroz Simões. "Immunological serum markers for hepatitis viral infections: HAV, HBV, HCV to advance of genetic engineering." GSC Biological and Pharmaceutical Sciences 25, no. 1 (2023): 118–30. http://dx.doi.org/10.30574/gscbps.2023.25.1.0394.

Full text
Abstract:
Viral hepatitis is increasingly present in infections diagnosed around the world. Thousands of individuals are infected by these often-silent diseases that only manifest themselves when clinical signs are very advanced. Hepatitis A virus (HAV) is a vaccine-preventable liver infection. Recombinant vaccines had been applied with the advance of genetic engineering for HBV. New studies have investigated the improvement of the vaccine model of heterological antigens based on hepatitis B virus envelope protein containing HCV antigen as a chimeric vaccine. The aim of this study was to evaluate the de
APA, Harvard, Vancouver, ISO, and other styles
49

Andressa, de Farias Fehlberg, Lessa da Silva Joelma, Pinho Gomes Roberta, and Siqueira de Queiroz Simões Rachel. "Immunological serum markers for hepatitis viral infections: HAV, HBV, HCV to advance of genetic engineering." GSC Biological and Pharmaceutical Sciences 25, no. 1 (2023): 118–30. https://doi.org/10.5281/zenodo.10578863.

Full text
Abstract:
Viral hepatitis is increasingly present in infections diagnosed around the world. Thousands of individuals are infected by these often-silent diseases that only manifest themselves when clinical signs are very advanced. Hepatitis A virus (HAV) is a vaccine-preventable liver infection. Recombinant vaccines had been applied with the advance of genetic engineering for HBV. New studies have investigated the improvement of the vaccine model of heterological antigens based on hepatitis B virus envelope protein containing HCV antigen as a chimeric vaccine. The aim of this study was to evaluate the de
APA, Harvard, Vancouver, ISO, and other styles
50

Alhaqbani, Abdulaziz H., Abdulaziz Almusalam, Abdulaziz Alnadhari, et al. "The prevalence and associated factors of viral hepatitis and cryptogenic related hepatocellular carcinoma at King Abdulaziz Medical city-Riyadh." International Journal Of Community Medicine And Public Health 6, no. 2 (2019): 561. http://dx.doi.org/10.18203/2394-6040.ijcmph20190060.

Full text
Abstract:
Background: Worldwide, viral hepatitis is the major risk factor for HCC with hepatitis B (HBV) being more than hepatitis C (HCV). Saudi Arabia is one of the endemic areas of viral hepatitis. Cryptogenic HCC is thought to arias from unknown causes of liver cancers. Thus, the purpose of this study was to find the prevalence of viral and cryptogenic HCC in King Abdulaziz Medical City-Riyadh (KAMC-R).Methods: A retrospective chart review was performed for all HCC patients diagnosed between 2010 to 2017 at KAMC-R. Information regarding age, gender, comorbidity, alcohol consumption, serology tests,
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!